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Abstract 26 
The development of vaccines against herpes simplex virus (HSV) is an important global goal 27 
for sexual and reproductive health. A key priority to advance development of HSV vaccines 28 
is the definition of preferred product characteristics (PPCs), which provide strategic 29 
guidance on World Health Organization (WHO) preferences for new vaccines, specifically 30 
from a low- and middle-income country (LMIC) perspective. To start the PPC process for HSV 31 
vaccines, the WHO convened a global stakeholder consultation in March 2017, to define the 32 
priority public health needs that should be addressed by HSV vaccines and discuss the key 33 
considerations for HSV vaccine PPCs, particularly for LMICs. Meeting participants outlined 34 
an initial set of overarching public health goals for HSV vaccines in LMICs, which are: to 35 
reduce the acquisition of HIV associated with HSV-2 infection in high HIV-prevalence 36 
populations and to reduce the burden of HSV-associated disease, including mortality and 37 
morbidity due to neonatal herpes and impacts on sexual and reproductive health. 38 
Participants also considered the role of prophylactic versus therapeutic vaccines, the HSV 39 
types that should be targeted, important target populations, and infection and disease 40 
endpoints. This article summarizes the main discussions from the consultation. 41 
 42 
Keywords: Herpes simplex virus; sexually transmitted infections; vaccines; HSV vaccines; 43 
preferred product characteristics   44 
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1 Introduction 45 
Coinciding with the Decade of Vaccines and the Global Vaccine Action Plan, which calls for 46 
new research to expand the benefits of vaccination to all people, several global efforts have 47 
focused on the critical role of new innovations to improve sexual and reproductive health [1, 48 
2]. In the 2016 Global Health Sector Strategy for Sexually Transmitted Infections (STIs), 49 
vaccine development was noted as a key innovation for future STI control [2]. The World 50 
Health Organization (WHO), the US National Institutes of Allergy and Infectious Diseases and 51 
global technical partners have outlined a comprehensive roadmap for development of 52 
effective new vaccines against STIs [3, 4]. The roadmap highlights the importance of 53 
focusing on herpes simplex virus (HSV) vaccine development because: (a) over half a billion 54 
people are estimated to have genital HSV infection globally [5, 6]; (b) HSV-2 is the leading 55 
cause of genital ulcer disease (GUD) worldwide; (c) HSV-2 fuels the HIV epidemic by 56 
increasing the risk of HIV acquisition and transmission [7]; (d) current HSV prevention 57 
measures have limited population impact [7]; and (e) product development of new 58 
candidate vaccines is more advanced for HSV than for other STIs, with the exception of 59 
human papillomavirus (HPV), for which approved vaccines already exist. In 2016, the need 60 
for HSV vaccines for global use was further highlighted by WHO’s Product Development for 61 
Vaccines Advisory Committee [8]. 62 
Two priority activities have been identified by WHO to facilitate and accelerate the 63 
development of HSV vaccines for global use. The first is defining preferred product 64 
characteristics (PPCs), which provide strategic guidance on WHO’s preferences for new 65 
vaccines, specifically from a low- and middle-income country (LMIC) perspective [9]. PPCs 66 
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are pathogen-, rather than product-specific, and summarize the preferences for parameters 67 
such as indications, target groups, immunization strategies, safety and efficacy, to address 68 
priority global public health and programmatic needs. The second activity is developing a 69 
value proposition (or investment case) for HSV vaccines that incorporate these PPCs, from a 70 
global public health perspective. 71 
As a first step in defining PPCs for HSV vaccines, WHO convened a stakeholder consultation 72 
in March 2017 with HSV experts from academia, industry, and clinical medicine, as well as 73 
public health epidemiologists, regulators, and policymakers. The aims of this meeting were 74 
to: review data on HSV infection and disease, define the priority public health needs that 75 
should be addressed by an HSV vaccine, outline key considerations for establishing HSV 76 
vaccine PPCs, and assess how the current HSV vaccine pipeline aligns with public health 77 
need, especially for LMICs. This article summarizes the main discussions from the 78 
consultation. 79 
2 HSV infection and disease 80 
Two closely related HSV types cause human infection and disease. HSV-2 is almost 81 
exclusively sexually transmitted and causes genital infection. It is the leading cause of GUD 82 
globally. HSV-1 is mainly transmitted by oral contact to cause oral-labial herpes, but can also 83 
be transmitted to the genital tract to cause genital herpes. During primary genital infection 84 
with either HSV-1 or HSV-2, patients can experience multiple genital ulcers, which can last 85 
for up to three weeks without antiviral therapy, alongside systemic symptoms such as fever, 86 
myalgia and headaches [7]. Primary infection can also be asymptomatic or unrecognized 87 
(subclinical) but still renders the individual infectious to partners. After replication in 88 
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epithelial cells of the genital tract, HSV travels up neurons to lumbo-sacral ganglia where it 89 
establishes latency. The immune response typically clears the mucosal infection, but not the 90 
latent virus in the ganglia. Over many years, viral reactivation is frequent, particularly for 91 
HSV-2, resulting in repeated replication and shedding of infectious virus at the genital-92 
mucosal surface, with or without associated symptomatic recurrences of GUD. It had been 93 
thought that these reactivation episodes were rare, sporadic events; however, studies 94 
employing frequent genital swabbing [10] and modelling [11] suggest that HSV-2 infection is 95 
not a quiescent latent infection, but involves near-constant, low-grade release of virus from 96 
sensory neurons into the genital mucosa, where replication is controlled by local immune 97 
responses [11]. 98 
Up to 84% of shedding episodes are thought to be asymptomatic [12]. It has been estimated 99 
that transmission of HSV-2 is unlikely if the viral load during a shedding episode is less than 100 
104 copies of HSV-2 DNA; however, much higher levels of HSV-2 shedding (106 copies of HSV 101 
DNA) can be present even when lesions are very difficult to detect [13]. This is consistent 102 
with epidemiological observations that most HSV-2 transmission is due to asymptomatic 103 
shedding [14–16]. While estimates are based mainly on data from the USA, there has been a 104 
rigorous study of genital HSV-2 shedding conducted in Uganda that showed similar rates 105 
and quantities of total and subclinical shedding of virus [17]. However, whether 106 
transmission rates, particularly from asymptomatic shedding, are actually similar in LMICs 107 
and high-income countries (HICs) is not known. It is possible that transmission thresholds 108 
vary according to the presence of other genital infections, such as bacterial vaginosis, in 109 
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susceptible partners. In this regard, it has been shown that the quantity and frequency of 110 
HSV-2 shedding are increased in HIV co-infected people [18]. 111 
2.1 Epidemiology of HSV infection 112 
In 2012, an estimated 417 million people aged 15 to 49 years (range 274 to 678 million) 113 
worldwide were HSV-2-infected, equivalent to global prevalence of 11.3% [5]. Of these, 267 114 
million (64%) were women, who have greater biological susceptibility to HSV-2 infection. 115 
Africa contributed most to the global total due to its large population and high HSV-2 116 
infection prevalence (32%). South East Asia and the Western Pacific had lower prevalence 117 
(both 8%) but have large populations and, therefore, had high numbers of infected people 118 
(estimates of 74.6 million and 81.2 million, respectively). The global burden of HSV GUD has 119 
not been clearly elucidated, but assuming 10 to 20% of HSV-2 infected people have 120 
symptoms, and most recurrent GUD is related to HSV-2, an estimated 40 to 80 million 121 
people could have recurrent GUD worldwide [5]. 122 
By contrast, in 2012, the global prevalence of HSV-1 was 67% in 0 to 49 year olds (equivalent 123 
to 3.7 billion people), with most HSV-1 being acquired in childhood as an oral infection [6]. 124 
Acquisition of HSV-1 in childhood is however declining in several HICs such as the USA [19], 125 
so that increasing numbers of adolescents are susceptible to HSV-1 on initiation of sexual 126 
activity. Consequently, genital HSV-1 infection is now the leading cause of first episode 127 
genital herpes in some populations in HICs and is an important cause of genital herpes in the 128 
Americas, Europe and Western Pacific [6]. Overall, an estimated 140 million people have 129 
genital HSV-1 infection globally [6]. While the prevalence of genital HSV-1 infection is still 130 
thought to be relatively low in Africa and South East Asia [6], it is unknown whether the 131 
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proportion of individuals acquiring HSV-1 orally prior to adolescence may be starting to 132 
decrease in these regions as has been observed elsewhere [19], so that a growing number of 133 
people may first encounter HSV-1 via sexual contact. This is a gap in our understanding of 134 
HSV epidemiology globally. 135 
2.2 Neonatal herpes 136 
Neonatal herpes is the most severe direct clinical consequence of HSV infection. It usually 137 
results from exposure to either HSV-1 or HSV-2 in the genital tract during delivery, although 138 
in utero and postnatal infections can occur. It is associated with high mortality, having an 139 
estimated case fatality rate of 60% without treatment. Morbidity is also high, often in the 140 
form of long-term neurological disabilities regardless of treatment [20]. Globally, an 141 
estimated 14,000 cases of neonatal herpes occurred annually during 2010 to 2015 (range 142 
3,703 to 34,415 cases), equivalent to 10.3 cases per 100,000 births [20]. These estimates, 143 
however, rely heavily on data from studies in the USA, with only one study providing data 144 
on transmission risk [21]. The global estimates might under-estimate the number of cases in 145 
low resource settings, where Caesarean section rates can be lower and HIV prevalence 146 
higher than in HICs. There is a pressing need for primary data on the incidence of neonatal 147 
herpes in LMICs, especially in sub-Saharan Africa.  148 
2.3 HSV-2 interactions with HIV 149 
Epidemiologic studies have identified a complex and synergistic relationship between HIV 150 
and HSV-2 infections [22], raising the possibility that an effective HSV vaccine could have an 151 
important impact on the acquisition and transmission of HIV. 152 
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A recent meta-analysis found that the risk of HIV acquisition is approximately tripled in the 153 
presence of prevalent HSV-2 infection, and five times higher for those with incident HSV-2 154 
infection [23]. There are at least two possible mechanisms for this increased risk [24]: (a) 155 
breaks in the mucosa due to HSV-related ulcers that provide a more effective portal of entry 156 
for HIV [25]; and (b) HSV-2 infection and reactivation resulting in an infiltration into the 157 
genital mucosa of cells expressing receptors for HIV. Infiltration of CD4+ T cells expressing 158 
CCR5 or CXCR4 and DC-SIGN+ dendritic cells create a pool of target cells susceptible to HIV 159 
infection [26] (Figure 1). Increased densities of CD4+ T cells have also been detected in 160 
foreskin samples from HSV-2 infected, HIV-uninfected men [27]. 161 
In an effort to reduce the excess risk of HIV among HSV-2-infected people, two clinical trials 162 
evaluated the impact of daily suppressive therapy with oral acyclovir, an antiviral drug that 163 
can reduce the frequency and duration of HSV symptoms, on HIV acquisition [28, 29]. 164 
Suppressive acyclovir therapy did not reduce the risk of HIV acquisition in these trials, even 165 
when GUD was reduced [29]. Investigators have since observed that acyclovir treatment, at 166 
current doses, is insufficient to suppress the enrichment of T cells and dendritic cells in the 167 
genital mucosa stimulated by HSV-2 infection, which often persist long after ulcer healing 168 
[26]. These findings support the importance of HSV-induced mucosal infiltration of HIV 169 
target cells as a mechanism for enhanced HIV risk. 170 
HSV-2 infection is also implicated in an increased risk of HIV transmission. The presence of 171 
HSV-2-associated GUD has been estimated to increase the risk of HIV transmission 172 
approximately four-fold [30]. Higher HIV titres are found in genital secretions during HSV-2-173 
reactivation episodes, and HSV-2 proteins might upregulate HIV replication, increasing HIV 174 
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viral load in plasma [22]. Several studies have shown that acyclovir and valacyclovir can 175 
decrease the frequency and quantity of genital HIV shedding and the plasma load of HIV 176 
[31], and a large double-blinded randomized clinical trial [31], found that acyclovir reduced 177 
the HIV plasma load, and the amount of HIV RNA in male and female genital fluids. A clinical 178 
trial in HIV-discordant couples, however, found that suppressive acyclovir had no effect on 179 
HIV transmission to the HIV negative partner, although GUD in the HIV-infected partner was 180 
reduced by 73% [32].  181 
2.4 Other adverse outcomes 182 
Genital HSV infection can have important effects on sexual relationships and quality of life 183 
[33]. Genital herpes is often stigmatizing and the social consequences of the infection can 184 
have profound effects on sexual health and well-being, especially for adolescents and young 185 
adults.  186 
Although most vaccine-development efforts to date have focused on HSV-2 infection, a 187 
future HSV vaccine might be effective against both HSV-1 and HSV-2. Orolabial herpes 188 
affects hundreds of millions of people, and can cause severe gingivostomatitis in childhood. 189 
HSV-1 can also result in less common outcomes such as HSV keratitis, an important cause of 190 
infectious corneal blindness globally, and HSV encephalitis, the leading cause of sporadic 191 
viral encephalitis. 192 
2.5 Country perspectives 193 
Much of the data on epidemiology and burden of HSV disease have been collected from 194 
HICs, especially the USA. A broader global perspective is required to inform the WHO PPCs; 195 
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therefore, at the global stakeholder meeting, brief reports were presented on the nature 196 
and perception of HSV infection (including informal surveys and unpublished data) from 197 
Brazil, Burkina Faso, China, India, Kenya, South Africa and Zimbabwe. 198 
Awareness and perceptions of HSV infection and disease and its impact on health varied 199 
between countries. Common themes in these LMICs included a relatively low awareness of 200 
the burden of HSV-2-related disease outcomes, even when several in-country studies had 201 
collected data on HSV-2 seroprevalence. In countries in sub-Saharan Africa, concerns about 202 
the increased risk of HIV infection associated with HSV-2 and the increased severity of HSV 203 
GUD among HIV-infected people were paramount. However, these concerns might change 204 
somewhat with increased roll-out of anti-retroviral therapy and newly available HIV 205 
prevention measures such as pre-exposure prophylaxis. Representatives from other 206 
settings, such as India, suggested that other maternal and sexual health outcomes such as 207 
neonatal herpes might be more important to policy makers. Country representatives were 208 
uncertain whether current data were sufficient to convince policy makers and purchasers in 209 
LMICs of the public health need for an HSV vaccine.  210 
There has been little national policy-related activity regarding non-HIV STIs in many LMICs, 211 
although several have introduced HPV vaccines. HPV vaccines are, however, often promoted 212 
as anti-cancer rather than anti-STI vaccines, which can increase acceptability in adolescents 213 
and parents. Some discussion focused on the importance of an HSV vaccine to improve 214 
sexual and reproductive health generally. Many countries, including LMICs in Africa, are 215 
experiencing a youth bulge [34]; consequently, the need for, and potential impact of, 216 
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interventions targeting young people and those during their reproductive years in these 217 
countries could increase interest in HSV vaccines.  218 
3 Priority public health needs for HSV vaccines 219 
After reviewing the natural history and epidemiology of HSV infection and disease, meeting 220 
participants discussed the priority public health needs for HSV vaccines, particularly in 221 
LMICs. These discussions focused on the strategic goals of HSV vaccines, which can then 222 
guide more specific discussions on characteristics such as target populations, indications, 223 
clinical endpoints, safety and efficacy requirements, and vaccination strategies to meet 224 
these goals.  225 
During the meeting, the group proposed the following primary public health goals for HSV 226 
vaccines in LMICs:  227 
• to reduce the acquisition of HSV-2-associated HIV infection in high HIV-prevalence 228 
populations, and  229 
• to reduce the burden of HSV-associated disease, including mortality and morbidity 230 
due to neonatal herpes, and impacts on sexual and reproductive health.  231 
The group emphasized that the two goals listed above are in no particular order. The 232 
potential impact of HSV-2 vaccines on HIV infection could yield the most important 233 
reductions in morbidity and mortality and could strengthen the value proposition for 234 
investment in HSV vaccine development. However, because there are other existing and 235 
emerging tools for HIV prevention, such as broad delivery of anti-retroviral therapy and use 236 
of interventions such as pre-exposure prophylaxis, the role of HSV vaccines could become 237 
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less important to HIV prevention in the longer term. Furthermore, this goal only applies to 238 
areas of the world, such as sub-Saharan Africa, that have high prevalence of both HSV and 239 
HIV. Nonetheless, the meeting participants considered effective HSV vaccines to be an 240 
important strategy for HIV prevention, in addition to a range of other potential benefits.  241 
In discussing the goal of reducing HSV-associated disease, meeting participants recognized 242 
that neonatal herpes is the most devastating direct consequence of genital HSV infection 243 
but thought to be rare, although the true incidence of this condition is not fully understood. 244 
The value proposition for HSV vaccines will need to balance these considerations, and the 245 
collection of primary data on neonatal herpes in LMICs will inform future discussions on the 246 
global public health need.  247 
The burden of HSV-associated disease also includes overall effects on sexual and 248 
reproductive health, and several participants advocated for explicitly stating the benefits a 249 
vaccine would offer for sexual and reproductive health. It was emphasized that HSV 250 
infection has a range of potential adverse outcomes that, in sum, could drive the 251 
comprehensive impact of the vaccine beyond each individual disease outcome. The full 252 
range of effects on sexual and reproductive health – especially for young people – needs to 253 
be examined within the value proposition for HSV vaccines.  254 
Meeting participants agreed that, in considering the greatest public health need, the priority 255 
should be on development of vaccines against HSV-2, because of its demonstrated role in 256 
propagating the HIV epidemic, and as the primary source of recurrent GUD and neonatal 257 
herpes in LMICs. However, an HSV vaccine that protects against both HSV-1 and HSV-2 could 258 
have farther-reaching benefits than one that only protects against HSV-2 and would be 259 
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particularly important in HIC settings, where genital HSV-1 is an increasing cause of first-260 
episode genital herpes and an important cause of neonatal herpes [20]. More HSV-1 261 
seroprevalence data from LMICs could help determine whether similar trends in HSV-1-262 
related genital herpes and other outcomes will become important. 263 
4 Development of vaccines against HSV 264 
There are two broad approaches to developing vaccines against HSV: prophylactic 265 
(preventive) vaccines, to prevent new infections, and therapeutic vaccines, to treat or 266 
modify existing infections. There are currently no licensed vaccines against HSV-1 or HSV-2, 267 
but encouragement is provided by the development of therapeutic vaccines and a 268 
prophylactic vaccine against varicella-zoster virus, another human α-herpesvirus, closely 269 
related to HSV [35]. 270 
4.1 Prophylactic vaccines 271 
Prophylactic vaccines would be given before exposure to HSV, e.g., before first sexual 272 
contact (for prevention of HSV-2), or in infancy (for prevention of HSV-1). It is generally 273 
assumed that an effective prophylactic vaccine would act, at least in part, by inducing 274 
neutralizing antibodies against one or more of the 11 envelope proteins of HSVs. These 275 
include glycoprotein D (gD), which has been included in all candidate prophylactic HSV-2 276 
vaccines tested clinically to date, and/or glycoprotein B (gB), which was a component in 277 
earlier HSV-2 vaccines [36, 37].  278 
A few prophylactic vaccine candidates have been tested in clinical studies (Figure 2), the 279 
most advanced being a gD2-based vaccine with alum and monophosphoryl lipid A adjuvant 280 
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(GlaxoSmithKline, GSK). In a phase III trial, this vaccine showed 73% efficacy against GUD but 281 
only in a subset of participants: women who were seronegative for both HSV-1 and -2 when 282 
they entered the trial [38]. A second phase III trial (Herpevac), conducted only among 283 
women seronegative for HSV-1 and HSV-2, failed to show any protection against HSV-2 but 284 
did demonstrate 58% (95% CI, 12-80%) efficacy against HSV-1 GUD [39]. Efficacy against 285 
HSV-1 GUD appeared to correlate with anti-gD2 antibody titres [40]. The anti-HSV-1 activity 286 
may have been due to strong cross-reactivity between gD of HSV-1 and HSV-2, and greater 287 
susceptibility to neutralization for HSV-1 than HSV-2 [41].  288 
4.2 Therapeutic vaccines 289 
Therapeutic vaccines against HSV-2 would be given to individuals with a known history of 290 
HSV-2 disease, with the aims of reducing disease severity and shedding of HSV-2 (both 291 
asymptomatic and during GUD recurrences), thereby reducing transmission of HSV-2. 292 
Several different therapeutic vaccines have been, and are currently being, tested in phase 293 
I/II studies (Figure 2). An effective therapeutic vaccine is likely to act via cell-mediated 294 
immunity, possibly by stimulating resident memory T cells in the genital tract [42]. There is 295 
evidence that long-term resident CD8αα+ T cells at the dermis-epidermis junction in the skin 296 
of the genital tract might play a role in immune surveillance and containment of reactivation 297 
episodes [42]. If it is to control HSV release from sensory neurons and replication in mucosal 298 
epithelial cells, a therapeutic vaccine would need to induce a faster, more-effective immune 299 
response than that stimulated by reactivation episodes.  300 
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4.3 The HSV vaccine pipeline 301 
There are currently at least four HSV vaccines in clinical development, with at least one 302 
additional candidate likely to enter phase I studies in 2018, and all of the vaccines currently 303 
undergoing clinical testing are being evaluated as HSV-2 therapeutic vaccines. In addition, 304 
there are at least 20 candidates either in discovery or being researched by academic groups 305 
(Figure 2). Some of the candidates might also have potential as prophylactic vaccines 306 
because they include gD2 which has been a component of all prophylactic vaccines tested to 307 
date, although it should be noted that gD2 has not been shown to be an essential 308 
component for an HSV-2 prophylactic vaccine, nor does the inclusion of gD2 mean the 309 
vaccine will be effective. The key features of the HSV-2 vaccines currently in clinical trials are 310 
summarised in Table 1. None of these vaccines are being evaluated in LMIC populations. 311 
HSV vaccines based on many other formats and platforms are being evaluated pre-clinically, 312 
including whole-virus (killed, live-attenuated or genetically disabled), monovalent or 313 
multivalent subunits with adjuvants, DNA, mRNA, live-virus vectors, peptides and 314 
nanoparticle-based [35].  315 
4.4 Issues in the development of HSV vaccines 316 
Representative animal models do not currently exist for HSV infection or disease [35, 59], 317 
especially for the recurrent phase. For prophylactic vaccines, protection against intravaginal 318 
challenge in mice is often used; protection against the establishment of latency can also be 319 
tested in this model [56]. For both prophylactic and therapeutic vaccines, guinea pigs have 320 
been used because they experience a short period of recurrent genital disease after 321 
intravaginal HSV challenge [35]. Neither model has, however, been predictive of clinical 322 
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performance. Better animal models, possibly in non-human primates, could be used to 323 
screen candidates and de-risk vaccine development, particularly if the model exhibits 324 
recurrences following sexual transmission of the virus and/or long-term HSV shedding. 325 
There are no known immunological correlates of protection for prophylactic or therapeutic 326 
HSV-2 vaccines [59]. Furthermore, prophylactic vaccines require very large trials; for 327 
example, the Herpevac trial in the USA enrolled 8,323 females who were seronegative for 328 
both HSV-1 and HSV-2 [39]. In addition, HSV-2 prevalence is decreasing in some areas of the 329 
USA, e.g., by as much as 50% in Seattle [60], so efficacy trials of prophylactic vaccines may 330 
have to be even larger in these settings. In areas with high HSV-2 incidence rates, such as 331 
sub-Saharan Africa, trials could be conducted with fewer participants [61], provided the 332 
vaccine would be made available to these areas once developed. Importantly, for 333 
prophylactic vaccines based on whole-virus platforms, a new diagnostic test may be 334 
required to distinguish infected individuals from vaccinated individuals.  335 
In the past, GUD and/or infection (as measured by HSV-2 seroconversion) have been used as 336 
endpoints in phase III trials of prophylactic vaccines [38, 39]. From a technical standpoint, 337 
there is general consensus that it will be easier to achieve reduction in disease activity than 338 
to achieve complete immunity to infection [62]. Data from mouse models suggest that even 339 
if complete protection against infection is not achieved, vaccination can moderate the 340 
severity of primary infection and reduce the amount of virus establishing latency [56]. 341 
Murine models can be used to differentiate between vaccines that protect against disease 342 
and those that are functionally sterilizing, i.e. prevent infection [56, 58], but with the 343 
limitation that it is unclear if performance in mice is predictive of efficacy in humans.  344 
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For therapeutic vaccines, the frequency of HSV-2 shedding has been used as a primary 345 
endpoint in early phase trials, along with reduction in lesion rate and duration of recurrence 346 
(Table 1; [47, 51]). As an endpoint, frequency of shedding has the advantages of being 347 
relatively consistent over time within an individual and correlating with, but having more 348 
statistical power than, both lesion rate and recurrence history. This allows for a one-way 349 
crossover study design in which participants can serve as their own controls. Thus, 350 
adequately powered therapeutic vaccine trials can be done with fewer participants, and 351 
more quickly than prophylactic vaccine trials, which can potentially de-risk these studies for 352 
industry. Phase I and II trials of therapeutic vaccines have typically enrolled up to a few 353 
hundred subjects. 354 
5 Key considerations for HSV vaccine preferences for LMICs 355 
Given the priority public health needs discussed above, and the realities of HSV vaccine 356 
development and the vaccine pipeline, meeting participants discussed how to translate the 357 
strategic goals for HSV vaccines for LMICs into key considerations for HSV vaccine 358 
preferences. These discussions were intended to be the starting point for ongoing 359 
development of HSV vaccine PPCs. 360 
5.1 Vaccine approaches 361 
There was consensus that both prophylactic and therapeutic vaccines could play roles in 362 
achieving the public health goals for HSV vaccines, and that the two vaccine approaches are 363 
sufficiently different that separate PPCs (or sections) should be developed for each.  364 
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Prophylactic vaccines would be the most appropriate for use in LMICs for the goal of 365 
preventing HSV-2-associated HIV acquisition, because any HSV-2 infection, regardless of 366 
symptoms of GUD, increases HIV risk. Nonetheless, both prophylactic and therapeutic HSV 367 
vaccines might reduce risk of HIV acquisition if they decreased or modified symptomatic and 368 
asymptomatic HSV infection in a way that reduces micro-ulcerations and HSV-induced 369 
inflammatory target cells for HIV. Prophylactic vaccines could use existing vaccine-delivery 370 
infrastructure, for example targeting adolescents receiving HPV vaccines, whereas 371 
therapeutic vaccines would need to be delivered to individual HSV-infected patients within 372 
the health-care system. 373 
Several therapeutic HSV-2 vaccine candidates are in phase II trials in HICs, so a product 374 
might be available for implementation in LMICs sooner than for prophylactic vaccines. 375 
Therapeutic vaccines could be more attractive to vaccine developers (and investors) due to 376 
there being a sufficient market in HICs, and faster clinical development than for prophylactic 377 
vaccines. Therapeutic vaccines would, ideally, be at least as efficacious against GUD (and 378 
HSV transmission) as acyclovir. The effect of a therapeutic HSV vaccine on the increased risk 379 
of HIV acquisition among HSV-2-infected people remains unknown and could vary according 380 
to its immunologic mechanism and whether it may increase or decrease the presence of 381 
activated CD4+ T cells in the genital tract, which are targets for HIV infection [24].  382 
5.2. Target populations 383 
An HSV-2 prophylactic vaccine would most likely be offered to adolescents before first 384 
sexual exposure and immunity would need to last for at least the highest incidence period in 385 
young adulthood. Because many LMIC populations have high HSV-1 seroprevalence by 386 
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adolescence, HSV-2 prophylactic vaccines would need to be effective regardless of HSV-1 387 
serostatus. If protection against both HSV types is required and/or achievable, then 388 
prophylactic HSV vaccines could be administered during infancy, for this strategy, it is 389 
possible that booster doses would be required later in life.  390 
Therapeutic vaccines would most likely be offered to people with symptomatic GUD. To 391 
identify these people, they would need to seek care and be identified within an existing 392 
health care setting, such as primary care or family planning clinics. Implementation would 393 
be complex, as virologic assays for diagnosis of genital lesions may not be available and 394 
widely available serologic assays for HSV-2 infection are limited by poor specificity at the 395 
manufacturer recommended cut-offs [63]. Additional studies will be required to determine 396 
whether people with asymptomatic HSV infection, assuming they could be identified 397 
through serological screening, might also gain benefits from HSV vaccination. This might 398 
depend on whether the objectives are to reduce symptomatic HSV disease, reduce HIV 399 
acquisition, and/or prevent HSV or HIV transmission to sexual partners. Therapeutic 400 
vaccination of asymptomatic individuals would require the development of a diagnostic test 401 
(most likely blood-based) that is appropriate for use in LMICs.   402 
5.2 Potential HSV-vaccine outcomes and endpoints 403 
One key issue is whether an HSV vaccine needs to prevent infection or disease. Prophylactic 404 
vaccines preventing HSV infection would be ideal because (a) even asymptomatic infection 405 
is associated with increased HIV acquisition [7, 26], and (b) many neonatal herpes cases are 406 
related to incident, rather than pre-existing, maternal infection [20, 21]. However, HSV 407 
vaccines that modify, but do not prevent infection might also have an impact on important 408 
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outcomes. Modelling studies presented at the meeting suggest that even imperfect HSV-2 409 
vaccines (for preventing infection) could reduce HSV-2 incidence at the population level, 410 
especially when HSV-2 reactivation was reduced during breakthrough infection [64, 65]. 411 
Meeting participants emphasized that prophylactic vaccines do not need to induce an all-or-412 
nothing “sterilizing” immune response, but rather an important objective is reducing the 413 
probability of infection for most people, and modifying the infection in the remainder so 414 
they have reduced reactivation-related disease. It remains unclear whether reducing the 415 
clinical intensity of primary genital HSV-2 infection through vaccination will lead to less 416 
frequent or severe symptoms or HSV-2 shedding after acquisition. Table 2 outlines some 417 
possible outcomes of HSV vaccination and considerations related to endpoints, which will be 418 
further reviewed during the PPC process. 419 
5.3 Gaps in knowledge 420 
There are still gaps in knowledge that, if addressed, would greatly facilitate HSV vaccine 421 
development (Table 3). For several of the topics listed, there are data from HICs but the 422 
equivalent information is missing, or not recent, for LMICs.  423 
6 Conclusions 424 
Defining PPCs for HSV vaccines is a key priority for advancing development of HSV vaccine 425 
candidates that will have global benefits and will be suitable for use in LMICs. The March 426 
2017 WHO HSV vaccine global stakeholder consultation laid the groundwork for developing 427 
these PPCs, by defining priority public health needs that should be addressed by HSV 428 
vaccines and discussing key considerations for establishing HSV vaccine preferences for 429 
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LMICs. Meeting participants concluded that the global public health goals for HSV vaccines, 430 
in no particular order, should be reducing acquisition of HSV-associated HIV in high-431 
prevalence populations and reducing the burden of HSV-associated disease, including 432 
mortality and morbidity due to neonatal herpes and impacts on sexual and reproductive 433 
health. The meeting attendees considered these goals to have similar priority, and sexual 434 
and reproductive health was highlighted as a framework around which multiple potential 435 
benefits of an HSV vaccine (e.g., preventing GUD and psychosocial sequelae) could be 436 
brought together. The group noted that the PPCs will need to be defined in parallel with 437 
generation of a public health value proposition for HSV vaccines, to attempt to quantify and 438 
weigh different aspects of the public health need with the potential costs and benefits of 439 
HSV vaccines in addressing that need.  440 
In addition to HSV prophylactic vaccines, which would be ideal for LMIC use, the therapeutic 441 
HSV-2 vaccines that are the current focus of development efforts for HICs could also play an 442 
important role in addressing global public health need. Meeting participants agreed that 443 
PPCs should be defined for each. A working group, established by WHO, will now prepare 444 
draft PPCs, which will then be circulated for open comment from a larger group of 445 
stakeholders, before being finalized and communicated by WHO. The discussions from this 446 
consultation meeting, addressing considerations such as which HSV types should be 447 
targeted, vaccine indications, important target populations, infection and disease endpoints, 448 
critical efficacy and safety considerations, and pertinent vaccination strategies, will serve as 449 
the basis for defining and finalizing comprehensive PPCs for HSV vaccines. 450 
  451 
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Table 1 721 
Summary of leading HSV vaccines in clinical and preclinical development, March 2017 722 
Vaccine; 
developer 
Composition Type Status  Data 
COR-1; 
Admedus 
DNA: a mixture of two plasmids 
coding for full length gD2, and 
truncated gD2 with a ubiquitin tag; 
codon optimized. 
Thera
peutic 
Phase II Preclinical: [43]. 
Phase I. T-cell responses in 19 of 20 subjects; 
no increase in antibody response [44]. 
HerpV; 
Agenus 
Subunit plus adjuvant: Thirty-two 
35-mer peptides, complexed with 
human heat shock protein 70, plus 
QS-21 adjuvant. 
Thera
peutic 
Not known Preclinical: [45]. 
Phase I: Boosting of CD4+ and CD8+ T cells [46]. 
Phase II: 15% reduction in shedding [47]. 
GEN-003; 
Genocea 
Subunit plus adjuvant: truncated 
gD2 plus 39.2 kD fragment of ICP4 
(infected cell protein 4) plus Matrix 
M2 adjuvant. 
Thera
peutic 
Phase II Preclinical: [48, 49]. 
Phase I/IIa: Boosting of T cells (γ-interferon 
producing) and antibodies [50]. Reduction in 
HSV-2 shedding (31 to 52%) and lesion rates 
immediately after dosing [51].  
HSV529; 
Sanofi 
Pasteur 
Live, genetically disabled: 
replication-defective HSV-2, with 
deletions of UL5 and UL29 genes. 
Thera
peutic 
Phase I Preclinical: [52–54]. 
Phase I: NCT01915212 and NCT02571166; data 
not available. 
VCL-HB01; 
Vical 
DNA plus adjuvant. DNA coding for 
HSV-2 UL46 (tegument protein 
VP11/12) and gD2, plus Vaxfectin® 
adjuvant. 
Thera
peutic 
Phase II Preclinical: [55–57]. 
Phase I/II: 49% reduction in lesion rate at 3 
months and 57% reduction in lesion rate at 9 
months in bivalent vaccine group; induction of γ-
34 
 
Vaccine; 
developer 
Composition Type Status  Data 
interferon-producing T cells [47] 
G103; 
Immune 
Design Corp 
 
Subunit plus adjuvant: trivalent gD, 
UL19 (truncated VP5, capsid) and 
UL25 (DNA packaging protein, 
structural); adjuvanted with 
proprietary glucopyranosyl lipid A 
in a stable emulsion (GLA-SE).  
Thera
peutic 
Preclinical; 
phase I 
scheduled 
for 2018. 
Preclinical: [58]. 
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Table 2 725 
Possible outcomes and clinical endpoint considerations for HSV vaccines 726 
Possible outcome 
of vaccination 
Advantages, notes Disadvantages, notes 
Prevention or 
reduction in HSV 
infection 
To the extent that HSV infections can be 
prevented, all HSV-related sequelae (such as 
GUD, neonatal herpes, increased HIV risk) will 
be prevented. Thus, this will have the largest 
impact for individuals. 
To have an impact on HIV risk, prevention of 
infection might be needed, because HSV-2 
increases HIV risk regardless of symptoms. 
Seroconversion can be used as an endpoint, 
especially if current assays are improved. 
Prevention of infection will be more difficult to 
achieve than prevention of disease. 
Vaccine developers are likely to prefer a less 
difficult endpoint: for example, in the first 
phase III trial of a gD2 prophylactic vaccine, 
there was 73% efficacy against disease, but 
only 38% efficacy against infection in women 
who were seronegative for both HSV-1- and 
HSV-2 [38].  
Prevention or 
reduction in GUD 
A vaccine could prevent the most important 
symptoms of genital herpes even if infection is 
not completely prevented. 
Could be a potential outcome of both 
prophylactic and therapeutic vaccination. 
There is likely to be a strong market for 
preventing or reducing GUD in HICs, which 
could help advance vaccine development for 
LMICs. 
It is not yet known if the societal cost of GUD 
alone is sufficient to justify HSV vaccine 
development and purchase for LMICs.  
The burden of HSV-related GUD and its effect 
on quality of life is unknown in many LMICs.   
36 
 
Possible outcome 
of vaccination 
Advantages, notes Disadvantages, notes 
Reduction in HSV 
shedding 
A vaccine could reduce HSV shedding and risk 
of transmission even if infection is not 
completely prevented. 
This could be a potential outcome of both 
prophylactic and therapeutic vaccination. 
Reduction in HSV shedding is relatively easy to 
measure and is likely to be a marker for 
disease activity and potential transmission to 
partners or neonates.  
The transmission threshold of HSV in humans 
is not known, and it is not clear how this data 
could be obtained.  
Assays could be developed that detect low 
levels of infection, sufficient to induce 
seroconversion but low enough that 
transmission doesn’t occur, or rarely (Table 3). 
Reduction in HSV 
transmission 
A vaccine could reduce HSV transmission even 
if infection is not completely prevented. 
Modeling suggests that even an imperfect HSV 
vaccine could reduce HSV incidence in a 
population [64]. 
Reduction in HSV transmission risk to a sexual 
partner may be a desirable characteristic for 
patients (for example for therapeutic vaccines 
in HICs) 
Direct measurement of HSV transmission 
following vaccination would be difficult, 
though not impossible, for example via 
discordant couple studies. 
The transmission threshold of HSV in humans 
is not known, and it is not clear how these data 
could be obtained.  
 
Reduction in HIV 
acquisition or 
transmission risk 
Reduction in HSV-related HIV infection could 
have a significant public health benefit, and 
would strengthen the public health 
investment case for HSV vaccines in LMICs. 
It might be difficult to measure impacts on HIV 
acquisition and transmission in clinical trials 
(though not impossible) and, therefore, be 
difficult to include as a primary indication for 
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Possible outcome 
of vaccination 
Advantages, notes Disadvantages, notes 
Modelling suggests that even an imperfect 
HSV vaccine could reduce HIV incidence in a 
population [64]. 
vaccination. 
Interest in effects on HIV compared with those 
on other outcomes will vary between 
countries, depending on HIV prevalence. 
Consideration will need to be given to the 
marginal benefit HSV vaccination could have 
on HIV given improved access to anti-retroviral 
therapy and new HIV prevention measures. 
Acyclovir has been shown to reduce GUD but 
without having an effect on HIV acquisition. A 
therapeutic vaccine would need to perform 
better than antivirals. 
The effect of therapeutic vaccines on 
modifying HIV risk requires evaluation. 
Prevention or 
reduction in neonatal 
herpes 
Neonatal herpes is the most severe direct 
outcome of HSV infection and its prevention 
could strengthen the public health value 
proposition for HSV vaccine development.  
Neonatal herpes is rare and so it will be 
difficult to measure as an outcome in clinical 
trials. 
The health and societal costs of neonatal 
herpes needs to be better quantified globally, 
balancing severe morbidity and mortality with 
its rare occurrence.  
Improved sexual and Improved sexual and reproductive health is Quality of sexual and reproductive health is 
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Possible outcome 
of vaccination 
Advantages, notes Disadvantages, notes 
reproductive health considered by some to be an important 
rationale for HSV vaccines, incorporating the 
totality of benefits of the vaccine.  
Data should be collected on the impact of HSV 
vaccines on exploratory endpoints such as 
relationships and quality of life. 
difficult to quantify. 
Existing quality of life scales for genital HSV 
need to be used to determine health utilities 
for HSV infection. 
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Table 3 728 
Gaps in knowledge 729 
 Gap Notes 
Clinical What is the level of HSV shedding (infectious 
dose) below which transmission of HSV-1 and 
HSV-2 does not occur? 
Knowing this threshold would allow for smaller 
clinical trials with virus shedding as a primary 
endpoint. It will, however, be very difficult to 
design human studies to define the infectious 
dose. 
This could also be important for genital HSV-1 
infections, where there are fewer symptomatic 
reactivations. 
 What are the asymptomatic transmission rates of 
HSV-1 and HSV-2 in LMICs? Can we assume they 
are the same as in HICs, and that they are 
responsible for most transmissions? 
It is possible that the transmission threshold(s) are 
different in LMICs compared with HICs due to 
differences in presence of other reproductive tract 
infections. 
 What is the burden of HSV-related GUD in LMICs? 
Is GUD regarded as a public health problem?  
What are the consequences of HSV-2 on the 
quality of life, including parameters such as 
mental health, productivity, and relationships? 
More epidemiological data need to be collected, 
using standardized protocols, to quantify the 
impact of HSV-associated disease in LMICs, and to 
develop a public health value proposition for HSV 
vaccines to present to stakeholders. 
 What is the burden of neonatal herpes in LMICs? There are very limited data from LMICs. Current 
estimates depend on data from studies in the USA 
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 Gap Notes 
only [20]. 
 How might a therapeutic vaccine affect the risk of 
HIV acquisition if it stimulates increased numbers 
of CD4+ T cells and dendritic cells in the genital 
mucosa? Can the potential risk be quantified in 
advance of clinical studies? 
It might be difficult to design studies to predict this 
risk, but this is an important question. The rate of 
HIV acquisition could be measured in large clinical 
trials in high-risk populations. 
 What are the best settings and populations for 
trials of prophylactic vaccines? 
Discordant couples might not be representative of 
the general population, and some HICs now have a 
low incidence of HSV-2 in some populations who 
usually volunteer for vaccine studies. Are there 
settings relevant to LMICs with sufficiently high 
HSV-2 incidence that could be used? 
Virology and 
immunology 
What are the correlates of protection from 
infection, disease and shedding, for prophylactic 
and therapeutic vaccines?  
Correlates of protection, especially for cell-
mediated immunity, are largely unknown for both 
HSV-1 and HSV-2. 
Data from clinical studies of varicella zoster virus 
therapeutic vaccines might provide information on 
potential cell-mediated immunity correlates that 
might be measurable in clinical studies with HSV 
therapeutic vaccines. 
In some HSV-1 studies, CD8+ T cell responses to 
specific regions of HSV and exhaustion markers on 
T cells in blood have been proposed as correlates 
of severity [66] . 
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 Gap Notes 
In most HSV clinical trials, peripheral blood is 
sampled for cell-mediated immunity, but the most 
relevant cells might be resident in the mucosal 
tissue and, therefore, less available for 
measurement. 
 An improved understanding of the neutralizing 
antibody responses to HSV-1 and -2 is needed, 
including epitope mapping and analysis of 
structure-function relationships. 
Higher-throughput assays for neutralizing 
antibodies, and with better specificity, will be 
required; some of which are being developed [67].  
 For use in future trials of prophylactic vaccines, is 
it possible to develop assays that measure 
prevention or reduction of future transmission of 
HSV? These could be used as an alternative to 
seroconversion and achievement of, so-called, 
sterilizing immunity. 
Serological studies (such as antibody avidity) or 
measurements of cell-mediated immunity (such as 
T-cell maturation) might predict risk of HSV 
transmission and could be used as surrogate 
endpoints. Measuring the amount of virus shed 
over a three-month period might be another 
option. 
 A better understanding of the sequence variation 
between different isolates of HSV from different 
geographic regions is needed [68] and is being 
developed [69]. 
The impact of genomic diversity on diagnostics, 
non-vaccine therapeutics and HSV-vaccine design 
and use also needs to be studied [7]. 
This should determine whether HSV vaccine 
development should focus on proteins that are 
more conserved between isolates and/or whether 
different vaccines are needed for different regions. 
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 Gap Notes 
Regulatory Which endpoint(s) will national regulatory 
authorities view as acceptable for licensing HSV 
prophylactic and therapeutic vaccines?  
Can effects on HIV be incorporated into the 
license (and label) for HSV vaccines? 
For first-generation HSV vaccines, clinical 
endpoints such as prevention of infection or GUD 
(for prophylactic vaccines) and reduction in GUD 
(therapeutic vaccines) may be most likely to be 
adopted by regulators  
If prevention of HIV is to be included as an HSV 
vaccine indication, HIV endpoints measureable in 
clinical trials are likely to be required.  
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 731 
Figure 1. Summary of the possible impacts of HSV-2 infection and HSV vaccines on HIV acquisition 732 
Upon HSV infection of Person B (HSV-2 susceptible partner) from Person A (HSV-2 source partner), initial 733 
mucosal replication results in establishment of latency in the dorsal ganglia, with subsequent reactivation 734 
episodes. Mucosal replication during initial infection or reactivation can result in HSV-associated genital ulcer 735 
disease (in Person B) and HSV transmission, through either asymptomatic or symptomatic HSV-2 shedding (to 736 
Person C). The presence of genital ulcers during primary infection or a reactivation episode, and infiltration of 737 
(CD4+) immune cells responding to either asymptomatic or symptomatic mucosal infection, increase Person B’s 738 
risk of HIV acquisition (from Person C). Prophylactic HSV vaccination of Person B could prevent HSV infection 739 
from Person A or reduce subsequent reactivation on breakthrough infection. Thereby, prophylactic HSV 740 
vaccination could reduce genital ulcer disease, HSV shedding, and infiltration of mucosal (CD4+) immune cells, 741 
which could decrease risk of HIV acquisition. Therapeutic vaccination of Person B after HSV infection could 742 
reduce reactivation of HSV, or could reduce genital ulcers and HSV shedding, and alter immune cells in the 743 
mucosa directly. Depending on the vaccine’s mechanism, it may increase or decrease activated CD4+ T cells in 744 
the genital tract, which could have varying effects on the risk of HIV acquisition.  745 
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 748 
Figure 2. Summary of the HSV vaccine pipeline 749 
